About: http://data.cimple.eu/news-article/272453ef6e6ba6a987df3f07466e7395b7dcea497bd071b02c8c9f1a

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/272453ef6e6ba6a987df3f07466e7395b7dcea497bd071b02c8c9f1a Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	Covid vaccine-maker AstraZeneca on Tuesday revealed it had hit a setback in trials of a treatment for the coronavirus. The drug, made from a combination of two antibodies, failed its main goal to treat Covid-19 symptoms in exposed patients, AstraZeneca said in a statement. The treatment has been undergoing phase 3 or final clinical trials to assess its safety and efficacy. AstraZeneca said that 1,121 unvaccinated adults had been exposed to an infected person as part of the trial. Treatment AZD7442 reduced the risk of developing symptoms by only 33 percent -- which was "not statistically significant", it added. The company is nevertheless continuing trials to assess whether the drug can prevent Covid or treat more severe symptoms. The US government has funded the development of AZD7442 and has agreements to receive 700,000 doses. Meanwhile, AstraZeneca's Covid vaccine, which was developed with the University of Oxford, continues to face safety doubts. The jab has been suspended in several European countries over reports of rare blood clots. A top official in the European Medicines Agency on Sunday suggested that it might be worth abandoning AstraZeneca's coronavirus vaccine for all age groups where alternatives are available. However, a study from British health authorities showed on Monday that two doses of AstraZeneca/Oxford or rival Pfizer/BioNTech vaccines stopped the need for in-patient treatment in more than 90 percent of cases of the Delta variant. The UK government on Monday announced a four-week delay to the full lifting of coronavirus restrictions in England due to a surge in infections caused by Delta, which first appeared in India. jbo-rfj/bcp/pbr
schema:headline	AstraZeneca hits snag in Covid drug development
schema:mentions	European Medicines Agency England national football team Antibody Jab University of Oxford Delta Air Lines AstraZeneca Pfizer India Coronavirus disease United Kingdom Vaccine Severe acute respiratory syndrome coronavirus 2 Coronavirus disease 2019 Drug development Travys
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2021-06-15 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	neutral sentiment
http://data.cimple...readability_score	80 (xsd:integer)

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 11 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software